Content area

|
|

Virkninger af glukagonlignende peptider på galdeblæremotiliteten

Forfatter(e)
Ida Marie Gether1, Christina Nexøe-Larsen1, David Peick Sonne1, 2 & Filip Krag Knop1, 3, 4 1) Klinisk Metabolisk Fysiologi, Steno Diabetes Center Copenhagen,
Gentofte Hospital2) Klinisk Farmakologisk Afdeling, Bispebjerg og Frederiksberg Hospital3) Novo Nordisk Foundation Center
for Basic Metabolic Research, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet4) Institut for Klinisk Medicin, Det Sundhedsvidenskabelige Fakultet, Københavns Universitet

Ugeskr Læger 2018;180:V05180386
Reference: 
Ugeskr Læger 2018;180:V05180386
Sidetal: 

Ida M. Gether, Christina Nexøe-Larsen, David P. Sonne &
Filip K. Knop:

Effects of glucagon-like peptides on gallbladder motility

Ugeskr Læger 2018;180:V05180386

As cases of gallbladder-related adverse events have been reported in patients treated with glucagon-like peptide (GLP)-1 receptor agonists and GLP-2 receptor agonists, studies have investigated the effects of these hormones on the enterohepatic circulation of bile acids and gallbladder motility. Results suggest, that bile acids and GLP-2 counteract postprandial cholecystokinin-mediated gallbladder contraction, while GLP-1 may delay gallbladder refilling. This provides important information on the effect and safety of drugs based on GLP-1 and GLP-2, respectively.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Andreas Gothardt Lundh | 21/05
1 Kommentar
af Søren Dalsgaard | 20/05
1 Kommentar
af Anette Bygum | 19/05
10 kommentarer
af Hans-Iver G. F.-D Kley | 18/05
1 Kommentar
af Per Bonding | 17/05
1 Kommentar